Oxybutynin hydrochloride sustained-release capsule and preparation method thereof

A technology of oxybutynin hydrochloride and sustained-release capsules, which is applied in the field of capsules and its preparation, can solve the problems of frequent doses, large fluctuations in blood drug concentration, and large side effects, and achieve reduced doses, stable release curves, and reduced side effects Effect

Active Publication Date: 2016-01-06
上海爱的发制药有限公司
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ordinary tablets are taken more times, the blood concentration fluctuates greatly, and the side effects are large

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oxybutynin hydrochloride sustained-release capsule and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] The preferred embodiments of the present invention are given below in conjunction with the accompanying drawings to describe the technical solution of the present invention in detail.

[0015] Oxybutynin hydrochloride sustained-release capsules of the present invention are composed of the following components, calculated by weight percentage, 6.8% oxybutynin hydrochloride, 86.8% sugar pills, 1.3% hypromellose, 0.3% 35% Dimethicone emulsion, 3.7% ethyl cellulose aqueous dispersion, 0.8% dibutyl sebacate, 0.3% talc.

[0016] The hypromellose is a binder. The 35% (35% is the mass percentage, that is, 100 parts of the emulsion contains 35 parts of dimethicone) dimethicone emulsion is a water blocking agent, which prevents the water-soluble main ingredient from being absorbed during the coating operation. Penetrates into the coating film. The ethyl cellulose aqueous dispersion is a coating agent. The dibutyl sebacate is a plasticizer. Described talcum powder is lubricant...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an oxybutynin hydrochloride sustained-release capsule and a preparation method thereof. The oxybutynin hydrochloride sustained-release capsule is prepared from, by weight, 6.8% of oxybutynin hydrochloride, 86.8% of sugared pills, 1.3% of hydroxypropyl methylcellulose, 0.3% of 35% dimethicone emulsion, 3.7% of aqueous ethylcellulose dispersion, 0.8% of sebacic acid dibutyl ester and 0.3% of talcum powder. By means of the oxybutynin hydrochloride sustained-release capsule, effective blood concentration can be kept in vivo, no peak valley phenomenon is caused, side effects caused when the blood concentration is too high are relatively reduced, and meanwhile the non-treatment effect caused when the blood concentration is too low is reduced; the number of medicine taking times in each day is decreased, and the medicine taking compliance of patients is improved.

Description

technical field [0001] The invention relates to a capsule and a preparation method thereof, in particular to an oxybutynin hydrochloride sustained-release capsule and a preparation method thereof. Background technique [0002] Oxybutynin is a relaxant of urinary tract smooth muscle with mild anticholinergic and strong antispasmodic effects. It can selectively act on the detrusor muscle of the bladder, reduce bladder internal pressure, increase capacity, reduce involuntary bladder contraction, relieve urgency, frequency and incontinence. Oxybutynin is a major advance in the treatment of urinary incontinence, diseases that are becoming more prevalent with an aging population, such as prostate and bladder cancer, lower urinary tract symptoms in men, and urinary incontinence. [0003] At present, ordinary tablets are commonly used in clinical practice in China. The usual oral dose is 5 mg once, 2 to 3 times a day, and the maximum dose is 5 mg once, 4 times a day. Ordinary ta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/52A61K47/38A61P13/00
Inventor 雷迪克
Owner 上海爱的发制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap